메뉴 건너뛰기
Thrombosis Research
Volumn 122, Issue 6, 2008, Pages 725-726
Plasma clopidogrel metabolites and antiplatelet "resistance": Back to the future
Author keywords

[No Author keywords available]
Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DRUG METABOLITE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STREPTOKINASE;
EID: 52149085910     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.03.001     Document Type: Editorial
Times cited : (2)
References (7)
  • 1
    • 49249137412 scopus 로고    scopus 로고
    • Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction
    • Heestermans A.A., van Werkum J.W., Taubert D., et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res 122 (2008) 776-781
    • (2008) Thromb Res , vol.122 , pp. 776-781
    • Heestermans, A.A.1    van Werkum, J.W.2    Taubert, D.3
  • 3
    • 27644548513 scopus 로고    scopus 로고
    • Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial
    • COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621
    • (2005) Lancet , vol.366 , pp. 1607-1621
  • 4
    • 33645720938 scopus 로고    scopus 로고
    • Mortality benefit of no-load clopidogrel in COMMIT: not a surprise.
    • Serebruany V.L. Mortality benefit of no-load clopidogrel in COMMIT: not a surprise. J Cardiovasc Pharm Therap 11 (2006) 99-100
    • (2006) J Cardiovasc Pharm Therap , vol.11 , pp. 99-100
    • Serebruany, V.L.1
  • 5
    • 16844368927 scopus 로고    scopus 로고
    • A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite
    • von Beckerath N., Taubert D., Pogatsa-Murray G., Wieczorek A., Schomig E., Schomig A., et al. A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite. Thromb Haemost 93 (2005) 789-791
    • (2005) Thromb Haemost , vol.93 , pp. 789-791
    • von Beckerath, N.1    Taubert, D.2    Pogatsa-Murray, G.3    Wieczorek, A.4    Schomig, E.5    Schomig, A.6
  • 6
    • 27744516843 scopus 로고    scopus 로고
    • Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial
    • von Beckerath N., Taubert D., Pogatsa-Murray G., Schomig E., Kastrati A., and Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 112 (2005) 2946-2950
    • (2005) Circulation , vol.112 , pp. 2946-2950
    • von Beckerath, N.1    Taubert, D.2    Pogatsa-Murray, G.3    Schomig, E.4    Kastrati, A.5    Schomig, A.6
  • 7
    • 38949209538 scopus 로고    scopus 로고
    • Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome
    • Ho P.M., Peterson E.D., Wang L., Magid D.J., Fihn S.D., Larsen G.C., et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 299 (2008) 532-539
    • (2008) JAMA , vol.299 , pp. 532-539
    • Ho, P.M.1    Peterson, E.D.2    Wang, L.3    Magid, D.J.4    Fihn, S.D.5    Larsen, G.C.6

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.